Glenmede Trust’s Aimmune Therapeutics AIMT Stock Holding History

Glenmede Trust’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000	Closed	-$68K	–	2561
2020 Q3	$68K	Sell	2,000 -195	-9%	-$4.15K	﹤0.01%	1263
2020 Q2	$36K	Sell	2,195 -142	-6%	-$2.41K	﹤0.01%	1402
2020 Q1	$78K	Hold	2,337	–	–	﹤0.01%	1522
2019 Q4	$78K	Hold	2,337	–	–	﹤0.01%	1522
2019 Q3	$48	Buy	2,337 +347	+17%	+$7.08K	﹤0.01%	1677
2019 Q2	$41	Buy	1,990 +328	+20%	+$6.75K	﹤0.01%	1784
2019 Q1	$37	Buy	+1,662	New	+$39.1K	﹤0.01%	1829
2018 Q2	–	Sell	-17,481	Closed	-$661K	–	2438
2018 Q1	$661K	Hold	17,481	–	–	﹤0.01%	865
2017 Q4	$661K	Buy	+17,481	New	+$564K	﹤0.01%	865

Glenmede Trust's AIMT Position: Q4 2020 in Review

Glenmede Trust sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,000 shares — an estimated $68K sold.

Glenmede Trust first reported a position in AIMT in Q4 2017 and held it in 9 quarters. The position peaked at $661K in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Glenmede Trust reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 2,000 Aimmune Therapeutics shares in Q4 2020, an estimated $68K.
Glenmede Trust first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 9 quarters.
Glenmede Trust's Aimmune Therapeutics position peaked at $661K in Q1 2018.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.